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Abstract  
 
Background: The HLA-DRB*1501 haplotype influences the risk of developing multiple 
sclerosis (MS), but it is not known how it affects grey matter pathology.  
Aim: To assess HLA-DRB*1501 effects on magnetic resonance imaging (MRI) cortical 
grey matter pathology. 
Methods: Whole and lesional cortical grey matter volumes, lesional and normal-
appearing grey matter magnetization transfer ratio were measured in 85 people with MS 
and 36 healthy control subjects. HLA-DRB*1501 haplotype was determined by 
genotyping (rs3135388). 
Results: No significant differences were observed in MRI measures between the HLA-
DRB*1501 subgroups. 
Conclusions: The HLA-DRB*1501 haplotype is not strongly associated with MRI-visible 
grey matter pathology. 
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INTRODUCTION 
Significant progress has been made understanding the interplay between environmental 
and genetic factors in people who develop multiple sclerosis (MS). More than 100 gene 
loci have been found to influence the risk of a person developing MS, however the 
genetic factor most strongly associated with the development of MS is the polymorphism 
at the HLA-DRB1 locus, and in particular the HLA-DRB*1501 haplotype (International 
Multiple Sclerosis Genetics Consortium et al., 2007). HLA-DRB*1501 encodes a 
component of the histocompatibility complex II cell surface receptor necessary for 
antigen presentation (Hebbring et al., 2013), and this has been implicated in an aberrant 
T-cell mediated inflammatory response against myelin (International Multiple Sclerosis 
Genetics Consortium et al., 2007). Up to 30% of the European population are HLA-
DRB*1501 positive and this haplotype is associated with a 2-4 fold risk of developing 
MS (Dyment et al., 2004). Relatively little is known about whether or not the HLA-
DRB*1501 haplotype influences clinical and radiological manifestations of MS. 
Genotype-phenotype studies have shown that an HLA-DRB*1501 positive haplotype is 
associated with an earlier age at disease-onset (Masterman et al., 2000). However, 
associations with neurological and cognitive outcomes are less consistent. While some 
studies have found greater disability in HLA-DRB*1501 positive individuals (Okuda et 
al., 2009), other have found no (Barcellos et al., 2003) or less severe effects (Silva et al., 
2007).  
Only a few studies have looked for associations between genotype and magnetic 
resonance imaging (MRI) measures. Most have looked at the brain white matter (WM) 
only, and brain WM lesion loads - as seen on PD/T2-weighted MRI scans - appear to be 
greater in those who are HLA-DRB*1501 positive in some (Matsuoka et al., 2008; 
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Okuda et al., 2009) but not all studies (Zivadinov et al., 2003). Brain atrophy may also 
be greater in HLA-DRB*1501 positive compared with negative MS patients (Zivadinov et 
al., 2007), although not all studies have shown this (Van der Walt et al., 2011; Zivadinov 
et al., 2003). 
 
In this exploratory work, we looked for associations between the HLA-DRB*1501 
haplotype and MRI measures of cortical grey matter (cGM) pathology. 
 
PARTICIPANTS AND METHODS 
 
Participants 
Participants were between 18 and 65 years old, and had a diagnosis of MS based on 
the McDonald criteria (Polman et al., 2005). The control group had no known 
neurological disease. MS subtypes were classified using the Lublin-Reingold criteria 
(Lublin and Reingold, 1996). All participants gave written informed consent. This study 
has been carried out in accordance with The Code of Ethics of the World Medical 
Association (Declaration of Helsinki) and was approved by our local institutional ethics 
committee. Thirty relapsing-remitting (RR), 30 secondary progressive (SP), 25 primary 
progressive (PP) MS patients, and 36 healthy controls, were included in this study. In the 
30 days prior to scanning no patient had had a relapse or steroid treatment. Participants 
demographics and patients clinical characteristics are given in Table 1. 
 
Clinical assessments 
Expanded Disability Status Scale (EDSS, Kurtzke, 1983), MS Functional Composite 
(MSFC, Cutter et al., 1999) and Symbol Digit Modalities Test (SDMT, Smith, 1989) 
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scores were determined in the MS group. MSFC and SDMT scores were also assessed 
in controls to act as reference values. 
 
Image acquisition  
Using a 3T Philips Achieva system (Philips Healthcare, Best, The Netherlands) with a 
32-channel head coil and multi-transmit technology, T1-weighted volumetric, PSIR, 
PD/T2-weighted, fluid attenuated inversion recovery (FLAIR), and MTR were acquired.  
The acquisition parameters are given in Table 2. 
 
Image processing 
 
Lesion measures 
Cortical GM lesions were identified on the PSIR images, using JIM (Version 6.0, 
Xinapse Systems, Northants). Cortical GM lesions were subdivided into intracortical 
(lesions confined to GM) and leukocortical (lesions that involved both GM and WM). 
PD/T2-weighted and FLAIR-scans served as reference. Marking of all lesions was 
carried out blinded to clinical data under the guidance of an expert neuroradiologist (TY). 
 
Lesion and normal-appearing mask generation 
Registrations were performed using NitfyReg (Modat et al., 2010). The PSIR images 
(and corresponding lesion masks) were affine registered to the T1-weighted volumetric 
images. After lesion filling (Chard et al., 2010) the T1-weighted volume image was 
segmented to give GM and WM tissue probability maps using SPM8 (Wellcome Trust 
Centre for Neuroimaging, London, UK). Only voxels with a probability of ≥95% of being 
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GM or WM were included in subsequent analyses. The Montreal Neurological Institute 
(MNI)-152 T1-template was segmented using SPM8; cortical GM was manually 
extracted from the resulting GM mask using tools in the Functional Magnetic Resonance 
Imaging of the Brain Software Library (FSL, Oxford, UK) and affine registered to each 
subject’s T1-weighted volume image. A cortical NAGM mask was obtained by 
intersecting the thresholded GM mask for a given subject with the MNI-152 derived 
cortical GM mask, and then subtracting the intracortical and leukocortical lesion masks 
from this using tools in FSL.  
 
Magnetisation transfer ratio measures 
MTon and MToff images for each subject were affine registered to their T1-weighted 
volume images before calculation of the MTR. MTR (measured in percent units (pu)) 
was calculated for each voxel as MTR=(MToff-MTon)/MToff where MToff and MTon are the 
signal intensities without and with the application of the off-resonance pulse. With the 
MTR map, and lesion and tissue masks aligned with the T1-weighted volumetric images, 
MTR measures were extracted from each of the masked regions (cortical GM lesions, 
cortical NAGM). 
 
Brain volume measures 
After binarising SPM8 tissue probability masks using a maximum likelihood method, 
brain parenchymal fraction (BPF) was calculated by dividing the sum of the GM and WM 
volumes by the total intracranial volume, and similarly GM fraction (GMF) by dividing  
GM volumes by the total intracranial volume (Chard et al., 2010). 
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Image processing quality assessment 
All images were reviewed for artefacts, e.g. associated with subject motion; every 
registration step for every image was reviewed for accuracy. The segmented T1-
weighted images were reviewed. The registration steps and images of every tenth 
patient were re-reviewed by DTC for artefacts, registration and segmentation quality. 
Fifteen MTR scans from patients were rejected due to motion artefacts, and so this 
analysis included 70 patients and 36 controls. 
 
Genotyping 
DNA was extracted locally from blood using the standard Qiagen method and genotyped 
in the University College London Genomics Microarray Centre, using a custom-designed 
NeuroX genotype array from Illumina (San Diego, CA, USA). Genotyped data was 
assembled in GenomeStudio (Module Genotyping v1.9.4) per the manufacturer's 
suggestion (Illumina). Genotype result of rs3135388 was extracted and A-allele (Top 
allele) was counted as surrogate marker for HLA-DRB*1501. This has previously been 
shown to be highly sensitive and specific. Allele A of this single nucleotide polymorphism 
was shown to be highly associated with MS.(Benešová et al., 2013; International 
Multiple Sclerosis Genetics Consortium et al., 2007) 
 
Statistics 
Continuous data are presented as mean (± standard deviation [SD]). EDSS scores are 
presented as median (range). A Chi-Square Test was used to compare the disease 
modifying treatment (DMT), smoking status, gender and disease subtypes between the 
HLA-groups. General linear models were used to compare normally distributed 
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measures between HLA-DRB*1501-groups. Lesion volumes, MTR in lesions and 
cortical NAGM, EDSS, MSFC and SDMT were not normally distributed (all p<0.05, 
Shapiro-Wilk Test). For these measures we assessed between group differences using 
the Mann-Whitney U Test. A general linear model was used to determine if MRI 
measures and clinical measures differed between HLA-DRB*1501 groups. As age and 
gender can affect MRI measures, and as disease duration was significantly different 
between the HLA-groups, these variables, along with smoking status, previous and 
current disease modifying treatment (DMT), were all included in the model as 
covariates. All group comparisons were confirmed by bootstrap analysis (case re-
sampling, n=1000). Results were considered significant at a p<0.05 level. Where 
significant at this level, we also report if they remain so after Bonferroni correction. 
Sample size calculations were based on two group t-tests for differences between 
independent means. We used SPSS (Version 21, Chicago, IL, USA) for the statistical 
analysis. 
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RESULTS 
 
Genotyping 
All samples had call rates of > 99.5% and none was excluded due to poor calling. Call 
frequency for the rs3135388 was 100% and well-clustered (Figure 1).  
In total, 42/85 (49.4%) people with MS carried rs3135388 A allele and were inferred as 
HLA-DRB*1501 positive (homozygote A/A n=7, heterozygote A/B n=35).  
 
Patient demographics across the HLA-DRB*1501 groups 
Age and gender were not significantly different between HLA-DRB*1501 positive and 
negative patients (Table 1). 
 
Clinical outcome measures 
Measures of physical and cognitive disability were similar across the HLA-DRB*1501 
groups (Table 1). Differences between the HLA-DRB*1501 groups did not remain 
significant after Bonferroni correction. 
 
MRI outcome measures in MS and healthy controls 
Mean BPF, GMF, and cNAGM magnetization transfer ratio (MTR) were significantly 
lower in MS than healthy control subjects.  
 
MRI outcome measures across the HLA-DRB*1501 groups 
Mean BPF was higher in the HLA-DRB*1501 positive than negative MS group, but this 
did not remain significant after correction for multiple comparisons. GMF, cGM lesion 
volume, MTR in cGM lesions and cNAGM were similar between the HLA-DRB*1501 
groups (Table 2).  
 
Sample size calculation 
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Based on MTR differences between the two HLA-groups observed, sample size 
calculations estimate 83, 126 and 134 participants would be required in each group to 
detect a significant difference in cNAGM, cGM and mixed cGM-WM lesions, respectively 
(power 80%, alpha=0.05). 
 
DISCUSSION 
 
In this study, we investigated associations between HLA-DRB*1501 haplotype, a set of 
MRI measures sensitive to GM demyelination and neurodegeneration, and neurological 
and cognitive scores. We found no clear effect of HLA-DRB*1501 haplotype on the 
radiological or clinical disease burden. 
 
We have been able to find only one study (post-mortem, n=47, 80% SPMS) looking for 
associations of HLA-DRB*1501 haplotype with the extent of cGM lesions in the motor 
cortex (DeLuca et al., 2013) and, consistent with our whole brain results, no link was 
found. Similarly, we have identified a single study looking at GM MTR, and this was in a 
PPMS cohort (n=41) followed up over 5 years (Tur et al., 2014). Consistent with our 
findings, baseline GM MTR and GM volumes did not differ between the HLA-DRB*1501 
groups, however during follow-up GM MTR declined faster in the HLA-DRB*1501 
positive group (Tur et al., 2014). 
 
In the present study, BPF but not GMF appeared to be higher in the HLA-DRB*1501 
positive than negative MS group, although the effect was modest (about 1/3 of the 
difference seen between MS and controls), and when corrected for multiple comparisons 
the difference was not significant. Previous studies have yielded mixed results, either 
with greater GM atrophy in the HLA-DRB*1501 positive group (n=41, 34% progressive 
MS, Zivadinov et al., 2007), or no difference (n=41, 100% PPMS, Tur et al., 2014) These 
studies included different proportions of progressive MS patients and it is possible that 
HLA-DRB*1501 may have different effects in RRMS and progressive MS. 
 
The main limitation of this study is the low number of participants, which will have limited 
sensitivity to associations of MRI measures with HLA-DRB*1501. Power calculations 
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based on the result of the present study suggest that a substantially larger cohort would 
be required to demonstrate - if present - significant differences.  
While HLA-DRB*1501 is the best studied susceptibility allele in MS, the influence of 
HLA-regions is complex. Other HLA-variants have been linked with the risk of 
developing MS and subsequent disease severity, and these may interact with HLA-
DRB*1501: For example, Liguori et al. found in a longitudinal study of 518 people with 
MS, that in HLA-DRB1*1501 positive people, HLA-DRB1*10 was associated with a 
lower rate of WM lesion accrual (Liguori et al., 2011). Because of the limited number of 
subjects in our cohort we have focused on HLA-DRB1*1501 but future studies are 
warranted to explore the impact of other polymorphisms on MRI measures in MS. 
Moreover, ethnicity is an important factor in genetic analyses (Bove and Chitnis, 2014). 
In the present cohort, >90% of the patients were Caucasian, however, we have not 
performed a detailed genetic analysis of ethnicity. 
 
In conclusion, we found no evidence that HLA-DRB*1501 is a risk factor for greater MS 
disease effects in cortical GM, as assessed using a series of MRI measures sensitive to 
demyelination and neurodegeneration.  
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Table 1: Demographics and clinical features of patients and healthy controls. 
 
 Healthy 
Controls 
MS group  
HLA-DRB*1501 
P† 
  Positive Negative  
N 36 42/85 (49.4%) 43/85 (50.6%)  
Females 19/36 
(52.8%) 
27/42 (64.3%) 25/43 (58.1%) 0.658 
Age (years) 41.5±12.8 50.7±10.9 49.2±10.9 0.648 
MS subtype    0.922 
- RRMS NA 15/42 (35.7%) 15/43 (34.9%)  
- SPMS NA 14/42 (33.3%) 16/43 (37.2%)  
- PPMS NA 13/42 (31.0%) 12/43 (27.9%)  
Ever smoked  14/36 
(38.9%) 
33/42 (78.6%) 12/43 (27.9%) 0.012 
- Smoking years 5.0±9.6 15.3±13.8 11.4±15.0 0.209 
Age at disease onset 
(years) 
NA 31.1±11.4 34.8±10.0 0.115 
Disease duration (years) NA 19.3 (11.0) 13.6 (9.8) 0.036 
EDSS, median (range) NA 5.0 (1-8) 5.0 (1-6.5) 0.641 
SDMT  61.8±9.5 47.79±10.85 43.66±11.98 0.034 
MSFC (z score) 0.35±0.26 -11.44±21.96 -10.65±19.91 0.265 
Current DMT NA 31/42 (73.8%) 28/43 (65.1%) 0.482 
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Previous DMT NA 15/42 (35.7%) 16/43 (37.2%) 0.886 
 
Mean±standard deviation unless stated otherwise.  
 
†Unadjusted p-values refer to the comparison between HLA-DRB*1501 positive and 
negative MS groups. There was no significant difference when adjusted for multiple 
comparisons (Bonferroni). 
 
Abbreviations: Expanded Disability Status Scale (EDSS), MS Functional Composite 
(MSFC, z-score) and Symbol Digit Modalities Test (SDMT) scores were determined in 
the MS group. MS = multiple sclerosis, RR = relapsing-remitting, SP = secondary-
progressive, PP = primary-progressive, DMT Disease modifying treatment, NA not 
available. 
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Table 2: MRI acquisition parameter. All images were aligned to the anterior posterior 
commissure line.  
 
 T1 PSIR PD/T2 FLAIR MTR ¶ 
Dimension 3D 2D 2D 2D 3D 
Acquisition plane Sagittal Axial-
oblique 
Axial-
oblique 
Axial-
oblique 
Sagittal 
Resolution (mm3) 1x1x1 0.5x0.5x2 1x1x3 1x1x3 1x1x1 
FOV (mm2) 256x256 240x180 240x180 240x180 256x256 
Matrix 256x256 480x360 240x180 240x180 256x256 
TR (ms) 6.9 7301 3500 8000 6.4 
TE (ms) 3.1 13 19/85 125 2.7/4.3 
TI (ms) 824 400 - 2400 - 
Slices 180 75 50 50 180 
SENSE 2 - 1.7 1.3 - 
Time (min:sec) 6:32 11:26 04:01 03:44 26:00 
 
¶For the magnetization transfer ratio (MTR), a 3D slab-selective fast field echo sequence 
with two echoes was used. A turbo field echo readout was used, with an echo train 
length of four and turbo field echo shot interval of 32.5 ms giving a total time between 
successive MT pulses of 51.9 ms, and scan time of approximately 26 minutes. The two 
echoes were averaged (thereby increasing the signal to noise ratio) for both the MTon 
and MToff data used to calculate the MTR. Sinc-Gaussian shaped MT pulses with flip 
angle of 360° and 16 ms duration but in total, the time between MT pulses was 51.9 ms 
(including the MT pulse duration and gradients).  
 
 20 
Abbreviations: D = dimensional, TR = repetition time, TE = echo time, TI = inversion 
time, SENSE = sensitivity encoding factor, FOV = field of view, FLAIR = fluid attenuated 
inversion recovery, MTR = magnetization transfer ratio, PSIR = phase-sensitive 
inversion recovery, PD = proton-density. 
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Table 3: MRI measures of cortical grey matter pathology and fractional volumes 
 
MRI measures Healthy  
controls 
MS group 
HLA-DRB*1501 
 P† 
  Positive Negative  
Brain parenchymal 
fraction (%) 
82.2±1.6 80.2±1.8 79.5±2.2 0.038 
Grey matter 
fraction (%) 
47.7±1.2 47.2±1.1 47.1±1.6 0.570 
Intracortical lesion 
volume, ml 
0 0.448±0.308 0.461±0.524 0.958 
Leukocortical 
lesion volume, ml 
0 0.464±0.488 0.653±0.923 0.274 
MTR in 
cortical normal-
appearing grey 
matter  
32.6±0.8 31.3±1.3 30.9±1.2 0.160 
MTR in 
intracortical 
lesions  
NA 30.7±2.0 30.1±2.4 0.189 
MTR in 
leukocortical 
lesions  
NA 29.0±3.1 28.2±3.3 0.206 
 
† P-values for comparison of HLA-DRB*1501 positive vs. negative group, adjusted for 
gender, age, disease duration, current and previous disease modifying treatment and 
smoking status (general linear model, confirmed by bootstrap analysis, case sampling 
n=1000).  
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There was no significant difference between the two HLA-DRB*1501 groups when 
adjusted for multiple comparisons (Bonferroni). 
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Figure 1: HLA-DRB*1501 genotyping. Call frequency for the rs3135388 was 100% and 
well-clustered. All samples had call rates of > 99.5% and none was excluded due to 
poor calling. 
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